Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies

JM Carrascosa, Martijn van Doorn, M Lahfa, FO Nestle, D Jullien, JC Prinz

Research output: Contribution to journalArticleAcademicpeer-review

53 Citations (Scopus)


Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an unwanted immune response. This immunogenicity may be associated with low trough drug levels, reduced clinical efficacy, reduced drug survival and an increased risk for adverse events. This article presents a literature review of the evidence on immunogenicity of biologics used in the treatment of psoriasis and considers the implications for therapeutic decision-making in the management of patients with moderate-to-severe psoriasis.
Original languageUndefined/Unknown
Pages (from-to)1424-1430
Number of pages7
JournalJournal of the European Academy of Dermatology and Venereology
Issue number11
Publication statusPublished - 2014

Research programs

  • EMC MM-03-61-05-A

Cite this